MX2016013711A - Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales. - Google Patents
Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.Info
- Publication number
- MX2016013711A MX2016013711A MX2016013711A MX2016013711A MX2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A MX 2016013711 A MX2016013711 A MX 2016013711A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- mglu2
- intellectual disabilities
- antagonists
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invención hace referencia a una nueva utilización médica de ciertos compuestos químicos y composiciones farmacológicas que los contienen. La invención hace referencia a compuestos que son moduladores alostéricos negativos de mGlu2/3 para su utilización en el tratamiento de varias discapacidades intelectuales. En otro aspecto, la invención hace referencia a una composición farmacológica para su utilización en el tratamiento de varias discapacidades intelectuales que incluye un compuesto de acuerdo con la invención y un transportador farmacológicarnente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14165632 | 2014-04-23 | ||
PCT/EP2015/058466 WO2015162076A2 (en) | 2014-04-23 | 2015-04-20 | Mglu2/3 antagonists for the treatment of intellectual disabilities |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016013711A true MX2016013711A (es) | 2017-01-13 |
Family
ID=50513799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016013711A MX2016013711A (es) | 2014-04-23 | 2015-04-20 | Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20170035767A1 (es) |
EP (1) | EP3134089A2 (es) |
JP (1) | JP2017513844A (es) |
KR (1) | KR20160143853A (es) |
CN (2) | CN106132966A (es) |
AR (1) | AR100151A1 (es) |
BR (1) | BR112016021727A2 (es) |
CA (1) | CA2943877A1 (es) |
MA (1) | MA39901A (es) |
MX (1) | MX2016013711A (es) |
RU (1) | RU2016144702A (es) |
WO (1) | WO2015162076A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202106872D0 (en) * | 2021-05-13 | 2021-06-30 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0014859A (pt) | 1999-10-15 | 2002-07-16 | Hoffmann La Roche | Derivados de benzodiazepina |
ATE261945T1 (de) | 1999-10-15 | 2004-04-15 | Hoffmann La Roche | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
ATE287883T1 (de) | 2001-04-12 | 2005-02-15 | Hoffmann La Roche | Dihydro-benzo(b)(1,4)diazepin-2-on-derivate als mglur2 antagonisten |
NZ528315A (en) | 2001-04-12 | 2005-04-29 | F | Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as MGLUR2 antagonists II |
US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
DE10330447A1 (de) | 2003-07-05 | 2005-02-10 | Daimlerchrysler Ag | Vorrichtung und Verfahren zum Vergleich von Bauteilen |
DK1651234T3 (da) | 2003-07-25 | 2008-01-28 | Hoffmann La Roche | Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser |
JP4608542B2 (ja) | 2004-06-21 | 2011-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | ピラゾロピリミジン誘導体 |
ES2365406T3 (es) | 2005-02-11 | 2011-10-04 | F. Hoffmann-La Roche Ag | Derivados de pirazolo-pirimidina como antagonistas de mglur2. |
CN101180299B (zh) | 2005-03-23 | 2010-12-15 | 弗·哈夫曼-拉罗切有限公司 | 作为mglur2拮抗剂的乙炔基-吡唑并嘧啶衍生物 |
ES2340321T3 (es) | 2005-09-27 | 2010-06-01 | F.Hoffmann-La Roche Ag | Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2. |
WO2007110337A1 (en) * | 2006-03-29 | 2007-10-04 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
US8012986B2 (en) | 2007-04-02 | 2011-09-06 | Hoffmann-La Roche Inc. | Pyridine and pyrimidine derivatives as MGLUR2 antagonists |
US9447099B2 (en) * | 2011-10-04 | 2016-09-20 | Hoffmann-La Roche Inc. | Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine |
EP2666775A1 (en) * | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
MX2015004604A (es) * | 2012-10-23 | 2015-10-08 | Hoffmann La Roche | Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas. |
-
2015
- 2015-04-20 CN CN201580014784.6A patent/CN106132966A/zh active Pending
- 2015-04-20 JP JP2016562009A patent/JP2017513844A/ja active Pending
- 2015-04-20 CN CN201910840522.5A patent/CN110483525A/zh active Pending
- 2015-04-20 CA CA2943877A patent/CA2943877A1/en not_active Abandoned
- 2015-04-20 MX MX2016013711A patent/MX2016013711A/es unknown
- 2015-04-20 BR BR112016021727A patent/BR112016021727A2/pt not_active Application Discontinuation
- 2015-04-20 WO PCT/EP2015/058466 patent/WO2015162076A2/en active Application Filing
- 2015-04-20 EP EP15716086.2A patent/EP3134089A2/en not_active Withdrawn
- 2015-04-20 RU RU2016144702A patent/RU2016144702A/ru unknown
- 2015-04-20 KR KR1020167032488A patent/KR20160143853A/ko unknown
- 2015-04-20 MA MA039901A patent/MA39901A/fr unknown
- 2015-04-22 AR ARP150101202A patent/AR100151A1/es unknown
-
2016
- 2016-10-21 US US15/331,466 patent/US20170035767A1/en not_active Abandoned
-
2018
- 2018-04-25 US US15/962,814 patent/US20180235971A1/en not_active Abandoned
-
2019
- 2019-04-17 US US16/387,384 patent/US20190343839A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR100151A1 (es) | 2016-09-14 |
CN106132966A (zh) | 2016-11-16 |
RU2016144702A (ru) | 2018-05-24 |
WO2015162076A3 (en) | 2015-12-10 |
US20180235971A1 (en) | 2018-08-23 |
EP3134089A2 (en) | 2017-03-01 |
CN110483525A (zh) | 2019-11-22 |
US20190343839A1 (en) | 2019-11-14 |
JP2017513844A (ja) | 2017-06-01 |
MA39901A (fr) | 2017-03-01 |
WO2015162076A2 (en) | 2015-10-29 |
BR112016021727A2 (pt) | 2017-08-15 |
US20170035767A1 (en) | 2017-02-09 |
CA2943877A1 (en) | 2015-10-29 |
KR20160143853A (ko) | 2016-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
HK1247822A1 (zh) | 用於活性劑口服給藥的製劑 | |
TN2017000511A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. | |
MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
PH12015502615B1 (en) | Chemical compounds | |
CA2956871C (en) | Compounds active towards bromodomains | |
PH12016501791A1 (en) | Muscarinic receptor agonists | |
MX2016010322A (es) | Compuestos aza biciclicos como agonistas del receptor muscarinico m1. | |
NZ737399A (en) | Ccr2 modulators | |
MX2015004604A (es) | Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas. | |
MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
TW201613864A (en) | Novel compounds | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX362879B (es) | Usos novedosos. | |
IL264880A (en) | Preparations for oral administration of active substances | |
PH12016500124A1 (en) | Via antagonists to treat phase shift sleep disorders | |
PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
PH12018501563A1 (en) | Indane derivatives as mglur7 modulators | |
MA39901A (fr) | Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles | |
NZ739679A (en) | Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
PH12017500346A1 (en) | Film coated tablet for the treatment of acute pain | |
AU2017900496A0 (en) | Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin |